Literature DB >> 1379425

Epitope specificities of human serum antibodies reactive with respiratory syncytial virus fusion protein.

B S Robinson1, J S Everson.   

Abstract

Respiratory syncytial (RS) virus continues to cause serious human respiratory disease and no prophylactic vaccine is yet available. Serum antibodies to RS virus fusion protein (F) that have the appropriate specificities and activities could confer protection against severe RS virus infections. To explore human serum antibody responses to RS virus F we first characterised four epitopes on F and then measured the concentrations of human serum antibodies to these sites for 389 sera. Individuals varied in serum antibody concentration to the epitopes. The distribution patterns of the concentrations of antibodies reactive to each epitope were different. Antigenic variation of F at these epitopes in Southampton RS virus isolates was examined by immunofluorescence. The F proteins from different isolates varied within and between RS virus subtypes which co-circulated in the outbreak of winter 1985-1986. Variations in F detected by immunofluorescence were consistent with differences between the strains' susceptibilities to monoclonal antibody antiviral action.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1379425     DOI: 10.1007/bf01309644

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  32 in total

1.  Comparative virulence of respiratory syncytial virus subgroups A and B.

Authors:  C E Taylor; S Morrow; M Scott; B Young; G L Toms
Journal:  Lancet       Date:  1989-04-08       Impact factor: 79.321

2.  The purification of four respiratory syncytial virus proteins and their evaluation as protective agents against experimental infection in BALB/c mice.

Authors:  E G Routledge; M M Willcocks; A C Samson; L Morgan; R Scott; J J Anderson; G L Toms
Journal:  J Gen Virol       Date:  1988-02       Impact factor: 3.891

3.  Identification of a synthetic peptide as part of a major neutralization epitope of respiratory syncytial virus.

Authors:  M Trudel; F Nadon; C Seguin; G Dionne; M Lacroix
Journal:  J Gen Virol       Date:  1987-09       Impact factor: 3.891

4.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

5.  Respiratory syncytial virus infections within families.

Authors:  C B Hall; J M Geiman; R Biggar; D I Kotok; P M Hogan; G R Douglas
Journal:  N Engl J Med       Date:  1976-02-19       Impact factor: 91.245

6.  Antibodies to respiratory syncytial virus polypeptides and their significance in human infection.

Authors:  K A Ward; P R Lambden; M M Ogilvie; P J Watt
Journal:  J Gen Virol       Date:  1983-09       Impact factor: 3.891

7.  Comparative analyses of the specificities of anti-influenza hemagglutinin antibodies in human sera.

Authors:  M L Wang; J J Skehel; D C Wiley
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

8.  Frequency of naturally occurring antibody to influenza virus antigenic variants selected in vitro with monoclonal antibody.

Authors:  A Natali; J S Oxford; G C Schild
Journal:  J Hyg (Lond)       Date:  1981-10

9.  Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants.

Authors:  C R Bangham; P J Openshaw; L A Ball; A M King; G W Wertz; B A Askonas
Journal:  J Immunol       Date:  1986-12-15       Impact factor: 5.422

10.  Monoclonal antibodies protect against respiratory syncytial virus infection in mice.

Authors:  G Taylor; E J Stott; M Bew; B F Fernie; P J Cote; A P Collins; M Hughes; J Jebbett
Journal:  Immunology       Date:  1984-05       Impact factor: 7.397

View more
  3 in total

1.  Respiratory syncytial virus--how soon will we have a vaccine?

Authors:  G L Toms
Journal:  Arch Dis Child       Date:  1995-01       Impact factor: 3.791

2.  Antigenic analysis of the F protein of the bovine respiratory syncytial virus: identification of two distinct antigenic sites involved in fusion inhibition.

Authors:  J P Matheise; K Walravens; A Collard; P Coppe; J J Letesson
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

3.  Subgrouping of respiratory syncytial virus strains from Australia and Papua New Guinea by biological and antigenic characteristics.

Authors:  J C Hierholzer; G A Tannock; C M Hierholzer; R A Coombs; M L Kennett; P A Phillips; I D Gust
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.